Evidence map›Paper›PMID 29225622›Full record

ArticleInternational journal of endocrinology2017

Correlation between CH

Anna Szczepańska-Szerej, Jacek Kurzepa, Aneta Grabarska, Joanna Bielewicz, Ewa Wlizło-Dyś, Konrad Rejdak

Open access · goldAbstract read
In one paragraph

Article in International journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anna Szczepańska-SzerejDepartment of Neurology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-0660-6698
Jacek KurzepaDepartment of Medical Chemistry, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-7524-8831
Aneta GrabarskaDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Joanna BielewiczDepartment of Neurology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-2211-7341
Ewa Wlizło-DyśDepartment of Neurology, Medical University of Lublin, Lublin, Poland.
Konrad RejdakDepartment of Neurology, Medical University of Lublin, Lublin, Poland.
Medical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine adipokines levels in patients with different etiologic subtypes of acute ischemic stroke (AIS) and metabolic syndrome (MetS) status.

methodsSerum adiponectin, leptin, and resistin levels were determined by ELISA in 99 AIS patients and 59 stroke-free control group subjects. Stroke patients were grouped based on MetS, modified TOAST classification, and CHA

resultsNo differences were found in all adipokine serum levels between AIS patients and appropriately matched control group. MetS-AIS patients had significantly higher leptin levels (22.71 ± 19.01 ng/ml versus 8.95 ± 9.22 ng/ml,

conclusionThis pilot study revealed that leptin could be a potential biomarker for risk stratification of cardioembolic stroke in MetS patients and that heterogeneity of stroke subtypes should be considered for more refined and precise clinical stroke studies.

Identifiers

PMID29225622
PMCPMC5684549
OpenAlexW2766837479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.